Pvct.Pk
PVCT.PK operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
Business. PVCT.PK operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PVCT.PK operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
PVCT.PK exhibits a highly leveraged capital structure, with total liabilities of $6,996,240 and total equity of -$6,298,740, resulting in a negative debt-to-equity ratio of -0.45. The company's liquidity position is weak, as indicated by a current ratio of 0.08, and it holds only $251,290 in cash and equivalents, which is insufficient to cover its $2,851,390 in long-term debt. The company's free cash flow is negative at -$5,503,260, and its operating cash flow is also negative at -$3,325,990, suggesting significant cash outflows.
Profitability is severely challenged, with a net loss of -$5,430,850 and an operating loss of -$5,294,760. The return on assets is -7.7862, and the return on equity is 0.8622, which is unusually high given the negative equity, likely due to the mathematical artifact of dividing a negative net income by a negative equity base. These metrics indicate that the company is not generating returns that meet industry expectations.
PVCT.PK's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. The company's revenue of $336,110 is relatively small, and there is no indication of geographic expansion or diversification in the segments or regions it operates in.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The negative operating and net income, combined with the lack of positive cash flows, suggests that the company is not currently in a growth phase. The absence of a clear growth strategy or significant revenue increases in the near term indicates a challenging outlook for PVCT.PK.
PVCT.PK faces significant financial risks, including a high liquidity risk due to its negative working capital and insufficient cash reserves to cover its obligations. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company has not made any adjustments to its valuation metrics, and there is no indication of recent dilutive events.
Recent events related to PVCT.PK include the filing of its latest financial statements, which disclose the company's poor financial performance and liquidity challenges. There are no recent transcripts or other disclosures that provide additional insight into the company's operations or strategic direction. The lack of positive developments or strategic initiatives in the recent filings suggests that the company is facing ongoing operational and financial difficulties.
- PVCT.PK has a highly leveraged capital structure with a negative debt-to-equity ratio and insufficient liquidity to meet its obligations.
- The company is experiencing significant financial losses, with a net loss of -$5,430,850 and an operating loss of -$5,294,760.
- PVCT.PK's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's growth trajectory is uncertain, with no clear signs of improvement in its financial performance or cash flows.
- PVCT.PK faces significant liquidity risks and has a negative net cash position after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- PVCT.PK Market data — financials · 2026-05-29
Ownership & reference
Leadership
- Ed V. PershingChairman of the Board, Chief Executive Officer
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): -87.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -7.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -16.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -1.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 15.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -18.3%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -1.11xDerived (calculated)
- Current ratio (FY 2025-12-31): 0.08xDerived (calculated)
- Return on assets (FY 2025-12-31): 789.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -5.7%Derived (calculated)
- Net margin (FY 2025-12-31): 1,637.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -45.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 0.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -30.7%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Revenue (annual): USD 336.11KSEC XBRL filing
- Operating cash flow (annual): USD -3.33MSEC XBRL filing
- Pre-tax income (annual): USD -5.51MSEC XBRL filing
- Net income (annual): USD 5.51MSEC XBRL filing
- Interest expense (annual): USD 5.34KSEC XBRL filing
- Shares outstanding (annual): 420.28MSEC XBRL filing
- Cash & equivalents (annual): USD 251.29KSEC XBRL filing